

A Model for in situ Plan of Care for a Critically Unstable Pediatric Patient Following I-131 MIBG Infusion.

Flori HR¹, Mwenesi R², Scott A³, Conrad CM⁴, Quinn JA⁵, Ostwani W⁶, Fischer KW⁵ and Yanik GA⁷.

¹ Heidi Rosanna Flori MD, FAAP. University of Michigan, Department of Pediatrics - Critical Care Medicine, Ann Arbor, MI

² Rama Mwenesi, University of Michigan, Department of Operating Room Administration

³ Annette Scott, MSN, RN, CNS University of Michigan, Department of Nursing (retired)

⁴ ChristinaMarie Conrad, MSN, RN, University of Michigan, Department of Professional Development and Education

⁵ Justin Andrew Quinn, CHP, Health Physicist, University of Michigan, Department of Environment, Health and Safety

⁶ Waseem Ostwani, MD, University of Toledo, Department of Pediatrics, Division of Pediatric Critical Care Medicine.

⁵ Karl William Fischer, CHP, Senior Health Physicist, University of Michigan, Department of Environment, Health and Safety

⁷ Gregory Anthony Yanik, MD, University of Michigan, Department of Pediatrics - Hematology/Oncology

Corresponding author:

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/psc.28665](https://doi.org/10.1002/psc.28665).

This article is protected by copyright. All rights reserved.

Heidi R Flori, MD

University of Michigan C.S. Mott Children's Hospital

Department of Pediatrics, Division of Pediatric Critical Care Medicine

1500 East Medical Center Drive

Ann Arbor, Michigan 48109

heidiflo@med.umich.edu

Abbreviations key:

MIBG	metaiodobenzylguanidine
PICU	Pediatric Intensive Care Unit
mrem	milli-rem
mSV	milli-sievert
mCi	milli-Curie
kg	kilogram
yo	year old
RT	Respiratory Therapist
MD	Medical Doctor
RN	Registered Nurse
hr	hour
HemeOnc	Hematology/Oncology

Abstract:

Recent clinical trials have moved I-131 MIBG therapy into frontline management of high-risk neuroblastoma. With this expansion, it is reasonable to anticipate the need for intensive care level resuscitations. Radiation exposure remains the greatest risk to healthcare professionals managing these patients. We combined shock simulation scenario data with actual radiation dosimetry data to create a care model allowing for aggressive, prolonged *in situ* resuscitation of a critically ill pediatric patient after I-131 MIBG administration. This model will maintain a critical care provider's radiation level below 10% of the annual occupational dose limit (5 mSv, 500 mrem) per patient managed.

Introduction:

Radioactive MIBG (metaiodobenzylguanidine) therapy is a targeted radiotherapy agent historically used for the treatment of relapsed or refractory neuroblastoma. Based upon promising response rates, recent clinical trials are moving MIBG therapy into front-line management of high-risk neuroblastoma.¹⁻⁸ Radiation exposure from iodine-131 (I-131) remains the greatest risk to healthcare professionals managing these patients.⁹⁻¹¹ In the United States, occupational radiation dose limits are found in Title 10, Part 20 of the Code of Federal Regulations (10 CFR 20), or in equivalent Agreement State regulations. The annual adult occupational dose limits are 50 mSv (5,000 mrem), and 5 mSv (500 mrem) for the embryo/fetus of a declared pregnant woman (during the entire pregnancy).^{11,12}

Due to Federal guidelines governing the release of individuals containing radioactive material (10 CFR 35.75),¹³ patients receiving I-131 MIBG treatment are typically hospitalized in a shielded isolation room for 3-5 days, pending clearance of the I-

131. In the event of acute, critical decline, it is undesirable for these patients to travel to diagnostic imaging or surgical suite facilities, or to have radioactive diagnostic samples sent to a clinical laboratory. During the infusion and in the days that follow, trained pediatric intensive care (PICU) and oncology team members are on-call to respond to emergencies including, but not limited to, sedation complications, anaphylaxis, septic shock, acute respiratory failure, cardiovascular instability (hypertensive crises, arrhythmias) and acute neurologic deterioration.

Radiation exposure to healthcare professionals for routine care of patients receiving I-131 MIBG treatment are historically very low (<0.45 mSv = 45 mrem per treatment).¹⁴⁻¹⁶ Unfortunately, these data do not reflect a potentially protracted time period at the bedside that would be required to adequately resuscitate a pediatric patient after severe, acute deterioration. Because multiple MIBG therapy patients are managed at Michigan Medicine annually, as part of our clinical practice guideline, we have established a radiation exposure goal of 5 mSv (500 mrem), or 10% of the annual occupational dose limit per healthcare professional per patient managed. Our goal was to create a care model that would allow for aggressive, *in situ* resuscitation of a critically ill pediatric patient after I-131 MIBG administration, while controlling occupational radiation doses for all care providers, to remain within our radiation exposure limit.

Methods:

A failure mode effects analysis identified staffing needs as our greatest barrier in resuscitating a patient with acute, severe shock immediately after MIBG infusion in the original acute care location. Therefore, we coupled dosimetry data from a

pediatric patient during and after MIBG infusion with data from a shock resuscitation simulation to generate a proposed staffing model.

Case Study: Concurrent with an existing MIBG treatment protocol approved by the Institutional Review Board, we placed five radiation dosimeters (Landauer OSL) in selected locations of the isolation room (Figure 1). An 11 yo female with high risk neuroblastoma received 811 mCi (15.1 mCi/kg) of I-131 MIBG. Dosimeters recorded exposure over selected time intervals for the first 96 hours after the infusion started.

Shock scenario simulation: We also completed a paper simulation of a patient experiencing an acute shock-type event after the start of MIBG infusion and requiring 4 days of intensive care management *in situ*. The scenario chosen was cardiac arrest, requiring full resuscitative efforts, including placement of monitors, rapid sequence intubation, mechanical ventilation and suctioning, peripheral, central venous and arterial vascular access completed in series, initiation and titration of vasoactive infusions, administration of sedation, analgesia, antibiotics and other medications, and emergent diagnostic testing. Emergent diagnostic testing for the deteriorated MIBG patient was limited to point-of-care blood testing and chest and abdominal radiographs.

The shock simulation scenario data were merged with dosimetry data to estimate radiation doses for each team member, accrued across all time phases for the first 4 days after MIBG administration. The scenario accounts for the dynamic movement of each team member among five different positions in the isolation room (**Table 1, Figure 1**) and radiation dose rate reduction from the physical decay¹⁵ of Iodine-131 and biological clearance of MIBG. Assuming team members work 8- or 12-hour

shifts, we determined the staffing model required to effect this same care in a real-life situation (**Supplemental Table**).

Results:

The highest dose rate is in position 2, at bedside and in front of the lead shield. Estimates indicate that a team member can remain in position 2 for the first 5 hours after infusion, the time of greatest radiation exposure, before reaching 5mSv (500 mrem). The next highest dose rate is in position 1 (head of the bed), although the dose rate was often less than 25% of the dose rate in position 2. Any position behind a lead shield results in substantially less exposure (**Table 1, Figure 1**).

The simulation resulted in time-spent estimates of 288 minutes for PICU nurse, 155 minutes for PICU physician, 146 minutes for oncology nurse, 58 minutes for oncology physician, and 76 minutes for PICU Respiratory Therapist (RT).

Taken together, these data determined our staffing model (**Supplemental Table**):

- a) *PICU physician*: Two pediatric intensivists will be necessary, each prepared to work 12-hour shifts for the first 96 hours after the start of MIBG infusion. A third intensivist should be available in the event that one of the two primary intensivists needs assistance.

- b) *PICU nurse*: For the first 24 hours, six PICUnurses will be needed, each working 8-hour shifts and rotating in 4-hour intervals between positions 2 and 3. After the first 24 hours, PICU nurses may work a 12-hour shift in all positions.
- c) *Respiratory therapist*: For all time periods, one RT will be needed and may work 12-hour shifts.

Discussion:

While maximal medical and surgical intensive care may not be an option for patients receiving MIBG therapy due to radiation safety concerns, this case study describes how critical care therapies may be safely applied *in situ* for the first 4 days after the start of the infusion. Our data indicate that a team member spending all time at the location of highest radiation dose rate (at bedside and in front of the shield) would not exceed 10% of the annual occupational dose limit, unless remaining in that position for more than 5 hours. The goal of 5mSv (500mrem) per patient allows team members to safely manage multiple patients annually, even in the unlikely event of multiple deteriorations.

As these data reflect one patient and one simulation, our proposed model recommends use of real-time dosimeters for quick, on-demand monitoring, worn by each team member, with accumulated doses assessed after the first 4 hours and at 24-hour intervals to assist in refining the need for staffing rotation. When possible, we recommend only one physician, nurse, and respiratory therapist be in the room, and team members should stand near the

door or behind a lead shield. Finally, should any team member exceed 5 mSv (500 mrem,)we recommend they rotate out of the isolation room into the anteroom (position 5) for all remaining time.

As MIBG treatment trials expand enrollment to include younger children and infants, as well as intravenous or multi-drug sedatives to ensure patient tolerance of the treatment, it is reasonable to anticipate the need for intensive care level resuscitations.¹⁷ Our model endorses that pediatric critical care level resuscitation and management can be achieved *in situ* while adequately controlling occupational radiation exposures.

Ongoing work is necessary to replicate our findings, perhaps with shorter monitoring periods, use of instantaneous monitoring, and in patients receiving different doses of I-131 MIBG.

ACKNOWLEDGEMENTS

Acknowledgement to Denise Regan, Nuclear Medicine Technologist, and the Michigan Clinical Research Unit for the many years of unending support of our MIBG program and its patients.

CONFLICTS OF INTEREST

The authors report no known conflicts of interest.

REFERENCES

1. Matthay K, Villablanca J, Seeger R, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplant and 12-Cis-Retinoic acid. *NEJM*. 1999;341:1165-1173.
2. Matthay K, George R, Yu A. Promising therapeutic targets in neuroblastoma. *Clin Cancer Res*. 2012;18(10):2740-2753.
3. Matthay K, Huberty J, Hattner R, et al. Efficacy and safety of 131-metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. *J Nucl Biol Med*. 1991;35:244-247.
4. Matthay K, Panina C, Huberty J, et al. Correlation of tumor and whole body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with 122 I-MIBG. *J Nucl Med*. 2001;42:1713-1721.
5. Howard J, Maris J, Kersun L, et al. Tumor response and toxicity with multiple infusions of high dose 131 I-MIBG for refractory neuroblastoma. *Pediatric Blood Cancer*. 2005;44:233-239.
6. Sharp S, Trout A, DeWeiss B, Gelfand M. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. *RSNA*. 2016;36:258-278.
7. Dubois S, Allen S, Bent M, et al. Phase 1/II study of 122 I-MIBG with Vincristine and 5 days of irinotecan for advanced neuroblastoma. *British Journal of Cancer*. 2015;112:644-649.
8. Shusterman S, Grant F, Lorenzen W, et al. Iodine-131-labeled meta-iodobenzylguanidine therapy of children with neuroblastoma: program planning and initial experience. *Semin Nucl Med*. 2011;41:354-363.
9. Turpin B, Morris V, Lemen L, et al. Minimizing nuclear medicine technologist radiation exposure during 131 I-MIBG therapy. *Health Phys*. 2013;104:S43-46.
10. Valentin J. International Commission on Radiological Protection 1997-2001. *Annals of the ICRP*. 2001;SE-171 16.
11. Dose equivalent to an embryo/fetus. In: Commission USNR, ed. 20.12081998.
12. Occupational Dose Limits. In: Commission USNR, ed: NRC Library; 2007.

13. Release of individuals containing unsealed byproduct material or implants containing byproduct material. In:2007.
14. Cougnenc O, Defachelles A, Carpentier P, et al. High dose 131I-MIBG therapies in children” feasibility, patient dosimetry and radiation exposure to workers and family caregivers. *Radiat Prot Dosimetry*. 2017;173(4):395-404.
15. Willegaignon J, Crema K, Oliviera N, et al. Pediatric 131I-MIBG therapy for neuroblastoma: whole body 131I-MIBG clearance, radiation doses to patients, family caregivers, medical staff and radiation safety measures. *Clin Nucl Med*. 2018;43(8):572-578.
16. Markelewicz R, Lorenzen W, Shusterman S, Grant F, Fahey F, ST T. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131 I-metaiodobenzylguanidine therapy. *Clin Nucl Med*. 2013;38(8):604-607.
17. Lee J, Wu R, Wong T, et al. Extended sedation with continuous midazolam or dexmedetomidine infusion for young children receiving 131 I-MIBG radiopharmaceutical therapy for advanced neuroblastoma. *Pediatric blood & cancer*. 2016;63(3):417-418.




FIGURE 1 Schematic of actual patient room noting each of 5 radiation dosimeter

locations. Dark lines represent portable lead shields. Double lines represent walls. Rectangle represents patient bed. Hexagons represent locations of dosimeters: 1 - at head of bed, 2 - at side of bed but in front of lead shield, 3 - at side of bed but behind lead shield, 4 – on wall within room, 5 – at doorway entrance to MIBG room

TABLE 1 Mean radiation doses (mrem/hr, 1mSv=100mrem) recorded over selected time intervals for the first 96 hours after I-131 MIBG infusion start at each of 5 patient room locations. (Note: *Exact time frame for this interval was 4 – 16.6 hrs.)

Time Period Dose Rate (mrem/hr)	0-4 hrs	4-16*hrs	16-24 hrs	24-48 hrs	48-75hrs	75-96 hrs
1 - Head of Bed	56	23	27	15	14	3
2 - Side of bed – in front of shield	103	89	96	59	34	21
3 - Side of bed – behind shield	5	2	1	<1	<1	<1
4 - Side wall of patient room	18	3	1	3	2	2
5 - Doorway to patient room	5	<1	<1	<1	<1	<1